Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-713-4 | CAS number: 98-92-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
Key value for chemical safety assessment
Skin sensitisation
Link to relevant study records
- Endpoint:
- skin sensitisation: in vivo (non-LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Non-GLP study.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 406 (Skin Sensitisation)
- Deviations:
- no
- GLP compliance:
- no
- Type of study:
- guinea pig maximisation test
- Species:
- guinea pig
- Strain:
- Pirbright-Hartley
- Sex:
- male/female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Age at study initiation: 8-9 weeks
- Weight at study initiation: 407-470 g (males), 380-466 g (females)
- Housing: Macrolon Type III cages with softwood granules, Type T, coarse I bedding (Fa H. Buntenback, D-5660, Solingen 11. One animal per cage.
- Diet (e.g. ad libitum): Standard experimental animal feed ad libitum, ssniff (G) individual diet, Fa. Ssniff Spezialfutter GmbH.
- Water (e.g. ad libitum): Ad libitum
- Acclimation period: 8 days under test conditions prior to substance application. Veterinarian observation of animals before the test start.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21 +/- 2
- Humidity (%): 55 +/- 15
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES:
- From: 12 November 1985
- To: 6 December 1985. - Route:
- intradermal and epicutaneous
- Vehicle:
- physiological saline
- Concentration / amount:
- 0.1 % via intradermal injection and a paste of 50 % (1 g/animal) during the induction phase. 25 % in challenge (provocation) phase.
- Route:
- epicutaneous, occlusive
- Vehicle:
- physiological saline
- Concentration / amount:
- 0.1 % via intradermal injection and a paste of 50 % (1 g/animal) during the induction phase. 25 % in challenge (provocation) phase.
- No. of animals per dose:
- 1 dose, 20 animals per dose. 20 animals in a control group.
- Details on study design:
- MAIN STUDY
A. INDUCTION EXPOSURE
- No. of exposures: 6 intradermal (2 x test substance solution, 2 x test substance solution/FCA (1:1), 2x FCA/physiological saline (1:1) + 2 day epicutaneous exposure.
- Exposure period: 8 days
- Test groups: 1
- Control group: 1
- Site: shoulder region, 6-8 cm region shaved prior.
- Frequency of applications: 1 daily for 6 days, intradermal, starting on the first research day, then 1 epidermal on the 8th research day
- Duration: 8 days total
- Concentrations: Intradermal: 0.1 % in physiological saline (0.9 % NaCl), with Freunds complete adjuvant (FCA, Difco Laboratories, Detroit, MI, USA). Epicutaneous: (48 h exposure via occlusive patch (Acrylastic, P, Beiersdorft and Co. AG, D-2000 Hamburg), on filter paper with plastic foil (2 x 4 cm), 1 g in 0.5 mL in physiologic saline
- Control: same treatment, however only the vehicle was applied rather than the test material.
B. CHALLENGE EXPOSURE
- No. of exposures: 1
- Day(s) of challenge: on research day 22
- Exposure period:: 24 h
- Test groups: 1
- Control group: same treatment as the animals in the test substance group
- Site: left flank for test substance, right flank for control. Flanks were shaved on the 22nd research day (approximately 5 x 5 cm)
- Concentrations:50 %, 50 mg/animal in physiological saline
- Evaluation (hr after challenge): 24 and 48 hours after removal of patch (Leukotest), on the 24th and 25th research days.
RANGE-FINDING STUDIES:
The maximum non-irritating concentrations for the intradermal and epidermal applications in the induction phase, as well as the non-irritating concentrations for the epidermal application in the provocation phase were determined in pilot tests on 2-3 guinea pigs respectively. - Challenge controls:
- A challenge control group was included (see details on study design).
- Positive control substance(s):
- no
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- negative control
- Dose level:
- 0
- No. with + reactions:
- 2
- Total no. in group:
- 20
- Clinical observations:
- weak erythema
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: negative control. Dose level: 0. No with. + reactions: 2.0. Total no. in groups: 20.0. Clinical observations: weak erythema.
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 0.1% induction, 25% challenge
- No. with + reactions:
- 9
- Total no. in group:
- 20
- Clinical observations:
- weak to mild erythema
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: test group. Dose level: 0.1% induction, 25% challenge. No with. + reactions: 9.0. Total no. in groups: 20.0. Clinical observations: weak to mild erythema.
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- negative control
- Dose level:
- 0
- No. with + reactions:
- 2
- Total no. in group:
- 20
- Clinical observations:
- weak erythema
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: negative control. Dose level: 0. No with. + reactions: 2.0. Total no. in groups: 20.0. Clinical observations: weak erythema .
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- 0.1% induction, 25% challenge
- No. with + reactions:
- 7
- Total no. in group:
- 20
- Clinical observations:
- weak to mild erythema
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: test group. Dose level: 0.1% induction, 25% challenge. No with. + reactions: 7.0. Total no. in groups: 20.0. Clinical observations: weak to mild erythema .
- Interpretation of results:
- not sensitising
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- The sensitisation potential of the test material was assessed in a guinea pig maximisation test. Nine of the twenty animals exposed displayed weak signs of erythema at 24 h, 7 of which persisted for 48 h, while two animals in the control group displayed erythema. This was determined to be non-significant in a statistical analysis. The test item is determined to be non-sensitising.
- Executive summary:
A study was carried out according to OECD Guideline 406 (Skin Sensitisation). The sensitisation potential of the test material was assessed in a guinea pig maximisation test. Twenty Pirbright White guinea pigs were intradermally administered the test substance with and without adjuvant, followed by one 48 h epidermal exposure to the test substance under an occlusive patch. After 3 weeks the animals were challenged with an epidermal patch of 50 % test material (50 mg) under an occlusive wrap for 24 h. Nine of the twenty animals exposed displayed weak signs of erythema at 24 h, 7 of which persisted for 48 h, while two animals in the control group displayed erythema. This was determined to be non-significant in a statistical analysis. The test item is determined to be non-sensitising.
Reference
Two of the control animals displayed weak erythema or edema at 24 and 48 h. Nine animals in the test group displayed weak to mild erythema, and this persisted in 7 of the 9 animals at 48 h. There was no systemic toxicity noted. Statistical analysis indicated that the incidence of positive skin reactions after nicotinamide exposure was not significant (p < 0.01).
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not sensitising)
- Additional information:
Key study - Guinea pig maximisation test
A study was carried out according to OECD Guideline 406 (Skin Sensitisation). The sensitisation potential of the test material was assessed in a guinea pig maximisation test. Twenty Pirbright White guinea pigs were intradermally administered the test substance with and without adjuvant, followed by one 48 h epidermal exposure to the test substance under an occlusive patch. After 3 weeks the animals were challenged with an epidermal patch of 50 % test material (50 mg) under an occlusive wrap for 24 h. Nine of the twenty animals exposed displayed weak signs of erythema at 24 h, 7 of which persisted for 48 h, while two animals in the control group displayed erythema. This was determined to be non-significant in a statistical analysis. The test item is determined to be non-sensitising.
Supporting study – Buehler test
A study was carried out according to OECD Guideline 406 (Skin Sensitisation). Ten Pirbright White guinea pigs were epidermally administered a 50 % dilution of a 5 % aqueous solution of test substance for 3 days, 6 hours per day, on days 1, 8 and 15, under an occlusive patch. This was followed on day 30 by one 6 h epidermal exposure to the test substance under the same conditions. Five control animals received physiological saline in the same procedure. Skin reactions were assessed at 24 and 48 h after patch removal using a scale of 0 to 4 to rank erythema and edema. None of the animals exposed to the test item displayed signs of sensitisation. The test item is concluded to be non-sensitising in the Buehler test.
Migrated from Short description of key information:
Two studies were carried out according to OECD Guideline 406 (Skin Sensitisation). In the key study sensitisation potential of the test material was assessed in a guinea pig maximisation test. In the supporting study the sensitisation potential was determined according to the Buehler test. Both studies determined the test item to be non-sensitizing.
Respiratory sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
Based on the data available the substance is not classified and labeled according to Regulation 1272/2008/EEC (CLP) and Directive 67/548/EEC (DSD).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
